New weight-loss drug dubbed the 'triple G' appears even MORE powerful than Ozempic, Wegovy, and Mounjaro - shedding 25% of patients' bodyweight The new injectable led to weight loss of nearly 25 percent, the most of any drug The drug is still in the middle stages and phase 3 is currently enrolling patients READ MORE: Hate needles
Regional accessibility supports consistent follow-ups and continuity of care for long-term results
Circadian variation in fat concentration of breast-milk in a rural northern Thai population
And in the phase 2 trial, it was very small, like 40 patients
Chia CW, Odetunde JO, Kim W, Carlson OD, Ferrucci L, Egan JM (2014) GIP contributes to islet trihormonal abnormalities in type 2 diabetes
5316, The Drug Shortage Compounding Patient Access Act PSM sent a letter explaining how H.R